Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

Trial ID or NCT#



not recruiting iconNOT RECRUITING


To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes

Official Title

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents

Eligibility Criteria

Ages Eligible for Study: 21 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Males/females aged ≥ 21 years and ≤ 65 years - Diagnosis of Type 2 Diabetes for ≤ 20 years - Obese individuals (BMI ≥ 30 kg/m2 and ≤ 55 kg/m2) - Stable doses (at least 3 months) of up to two anti-T2DM medications (MET, SU, DPP-4i or TZD) - Glycemic state: HbA1c at screening ≥ 7.5% and ≤ 10.0%. - Subjects willing to comply with study requirements - Subjects who have signed an informed consent form
Exclusion Criteria:
  1. - Diagnosis of type 1 diabetes mellitus or having any history of ketoacidosis - C-peptide < 1.0 ng/mL - Triglyceride level > 400 mg/dL - Vitamin D deficiency (<20 ng/mL) - Male subjects with serum Creatinine >1.5 mg/dl or female subjects with Creatinine >1.4 mg/dL - Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter, or known coagulopathy - Height < 5 feet (152.4 cm) - Current alcohol or drug addiction - Symptomatic kidney stones or gallstones within 6 months prior to randomization - Chronic pancreatitis or acute pancreatitis within 12 months of randomization - Diagnosis of osteoporosis or currently taking bisphosphonates or teriparatide - Diagnosis of an autoimmune connective tissue disorder (e.g., lupus erythematosus, scleroderma) - Active gastroesophageal reflux disease [GERD] uncontrolled with a Proton Pump Inhibitor (PPI) - Thyroid disease unless controlled with medication - Currently taking Non-Steroidal Anti-Inflammatory Drugs [NSAIDs] (e.g., aspirin, ibuprofen, etc.) within 10 days prior to randomization and/or there is a need or expected use of these agents during the trial 12 months post index procedure - Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to randomization and/or there is a need or expected need to use during the trial 12 months post index procedure - Currently taking systemic corticosteroids, drugs known to affect GI motility, prescription/over-the-counter weight loss medications, or medications known to cause significant weight gain or weight loss within 30 days prior to randomization and/or there is a need or expected need to use these medications during the trial 12 months post index procedure - Medication for type 2 diabetes other than MET, SU, DPP-4i, and TZD (e.g., GLP1 or insulin) within 3 months of screening - Chronic use of narcotics, opiates, benzodiazepines, or other addictive tranquilizers - Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, or any equivalent antibiotics - Active Helicobacter pylori infection (Note: Subjects may be eligible after undergoing 2 weeks of antibiotic treatment without re-screening) - Previous GI surgery or abnormal GI anatomical finding that could preclude the ability to place the EndoBarrier device, liner or affect the function of the liner - Abnormal pathologies or conditions of the gastrointestinal tract, including current ulcers or Crohn's disease, history of atresias or untreated stenoses, current upper gastrointestinal bleeding conditions within 3 months of randomization - Any condition or major illness that places the subject at undue risk by participating in the study - Poor dentition not allowing complete chewing of food - Enrolled in another investigational study within 3 months of screening for this study (Enrollment in observational studies is permitted) - Residing in a location without ready access to study site medical resources - Documented weight loss of >10 pounds anytime during the 3 months preceding randomization - Positive stool guaiac at time of screening


Marilyn Tan
Marilyn Tan
Clinical Associate Professor, Medicine - Endocrinology, Gerontology, & Metabolism

Contact us to find out if this trial is right for you.


Elizabeth Colbert